(VIANEWS) – CEGEDIM (CGM.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CEGEDIM (CGM.PA) | €16.40 | 2.94% | 5.4% |
| MERCK AND CO INC (MRK.PA) | €100.60 | 2.61% | 34.46% |
| BIOMERIEUX (BIM.PA) | €94.26 | 0.88% | 12.93% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CEGEDIM (CGM.PA)
2.94% Forward Dividend Yield and 5.4% Return On Equity
Cegedim SA operates as a technology and services company in the digital data flow management for healthcare ecosystem and B2B, and business software publisher for healthcare and insurance professionals worldwide. It operates in two divisions, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services division markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This division also provides solutions for hosting, HR and payroll management outsourcing, and electronic data exchange services. The Healthcare Professionals division offers management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was incorporated in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SA.
Earnings Per Share
As for profitability, CEGEDIM has a trailing twelve months EPS of €0.78.
PE Ratio
CEGEDIM has a trailing twelve months price to earnings ratio of 20.92. Meaning, the purchaser of the share is investing €20.92 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.4%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 29, 2022, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 2.94%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.5%, now sitting on 541.11M for the twelve trailing months.
Yearly Top and Bottom Value
CEGEDIM’s stock is valued at €16.40 at 06:30 EST, way below its 52-week high of €28.90 and way higher than its 52-week low of €13.56.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CEGEDIM’s stock is considered to be overbought (>=80).
More news about CEGEDIM.
2. MERCK AND CO INC (MRK.PA)
2.61% Forward Dividend Yield and 34.46% Return On Equity
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Earnings Per Share
As for profitability, MERCK AND CO INC has a trailing twelve months EPS of €5.37.
PE Ratio
MERCK AND CO INC has a trailing twelve months price to earnings ratio of 18.73. Meaning, the purchaser of the share is investing €18.73 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.46%.
Volatility
MERCK AND CO INC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.80%, a negative 0.17%, and a positive 1.25%.
MERCK AND CO INC’s highest amplitude of average volatility was 1.19% (last week), 1.51% (last month), and 1.25% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth grew by 2.3%, now sitting on 59.28B for the twelve trailing months.
More news about MERCK AND CO INC.
3. BIOMERIEUX (BIM.PA)
0.88% Forward Dividend Yield and 12.93% Return On Equity
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings Per Share
As for profitability, BIOMERIEUX has a trailing twelve months EPS of €3.41.
PE Ratio
BIOMERIEUX has a trailing twelve months price to earnings ratio of 27.64. Meaning, the purchaser of the share is investing €27.64 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.93%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.2%, now sitting on 3.59B for the twelve trailing months.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 6, 2022, the estimated forward annual dividend rate is 0.85 and the estimated forward annual dividend yield is 0.88%.
More news about BIOMERIEUX.
